3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Renal Cell
4
Prostatic Neoplasms
2
Bile Duct Neoplasms
2
Vulvar Neoplasms
1
Sarcoma
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neoplasm Metastasis
1
Hereditary Sensory and Autonomic Neuropathies
1
Gallbladder Neoplasms
1
Disease Progression
1
Clear-cell metastatic renal cell carcinoma
1
Cholangiocarcinoma
1
Carcinoma, Neuroendocrine
1
Breast Neoplasms
1
Interventions
pembrolizumab
6
Cetuximab
5
olaparib
3
atezolizumab
3
Injections
3
fludarabine
2
Trastuzumab
2
Docetaxel
2
Cyclophosphamide
2
Bevacizumab
2
zimberelimab
1
zansecimab
1
tocilizumab
1
taxane
1
spartalizumab
1
somatostatin receptor 2
1
ribociclib
1
pralsetinib
1
pertuzumab
1
pegylated granulocyte colony-stimulating factor
1
lenvatinib
1
ipatasertib
1
inavolisib
1
fludarabine phosphate
1
entrectinib
1
encorafenib
1
durvalumab
1
dapagliflozin
1
cemiplimab
1
brigimadlin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Solid Tumors
×
tivozanib
×
1 year
×
Clear all
No trials found.